Novuson Surgical

Novuson Surgical

Novuson's DTU technology represents the first substantial innovation in over 25 years for sealing vessels & dividing tissue in surgeries.

HQ location
Bothell, United States
Launch date
Employees
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor

€0.0

round
investor

€0.0

round

N/A

Early VC
Total Funding000k
Notes (0)
More about Novuson Surgical
Made with AI
Edit

Novuson Surgical, a spinout from the University of Washington's Applied Physics Center for Industrial and Medical Ultrasound, specializes in advanced energy technology for surgical and trauma procedures. The company has developed Direct Therapeutic Ultrasound (DTU) technology, a groundbreaking innovation in vessel sealing, dividing, and hemostasis (bleeding control). Novuson's products, such as the 3mm Mini LS and the 10mm UltraStat MAXX, are designed to improve surgical efficiency, reduce anesthesia time, and minimize the need for blood products, thereby enhancing patient outcomes and lowering healthcare costs. The company's primary clients include hospitals, surgical centers, and trauma units. Novuson operates in the medical device market, focusing on minimally invasive surgery and trauma care. The business model revolves around the sale of its proprietary medical devices, generating revenue through direct sales and potential licensing agreements.

Keywords: Direct Therapeutic Ultrasound, vessel sealing, hemostasis, surgical efficiency, trauma care, medical devices, minimally invasive surgery, healthcare cost reduction, patient outcomes, advanced energy technology.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo